- Home
- CANF vs SOS Comparison
CANF vs SOS Comparison
Compare CANF & SOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SOS
- Stock Information
- Founded
- CANF 1994
- SOS 2004
- Country
- CANF Israel
- SOS China
- Employees
- CANF N/A
- SOS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SOS Finance: Consumer Services
- Sector
- CANF Health Care
- SOS Finance
- Exchange
- CANF Nasdaq
- SOS Nasdaq
- Market Cap
- CANF 14.8M
- SOS 14.8M
- IPO Year
- CANF N/A
- SOS 2017
- Fundamental
- Price
- CANF $1.10
- SOS $6.37
- Analyst Decision
- CANF Strong Buy
- SOS
- Analyst Count
- CANF 2
- SOS 0
- Target Price
- CANF $14.00
- SOS N/A
- AVG Volume (30 Days)
- CANF 68.3K
- SOS 33.1K
- Earning Date
- CANF 06-17-2025
- SOS 05-15-2025
- Dividend Yield
- CANF N/A
- SOS N/A
- EPS Growth
- CANF N/A
- SOS N/A
- EPS
- CANF N/A
- SOS N/A
- Revenue
- CANF $674,000.00
- SOS $231,424,000.00
- Revenue This Year
- CANF $461.72
- SOS N/A
- Revenue Next Year
- CANF N/A
- SOS N/A
- P/E Ratio
- CANF N/A
- SOS N/A
- Revenue Growth
- CANF N/A
- SOS 150.42
- 52 Week Low
- CANF $0.98
- SOS $4.04
- 52 Week High
- CANF $4.69
- SOS $15.51
- Technical
- Relative Strength Index (RSI)
- CANF 46.91
- SOS 58.98
- Support Level
- CANF $1.07
- SOS $6.24
- Resistance Level
- CANF $1.12
- SOS $6.65
- Average True Range (ATR)
- CANF 0.03
- SOS 0.42
- MACD
- CANF 0.02
- SOS -0.01
- Stochastic Oscillator
- CANF 75.00
- SOS 59.69
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of big data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other service. The company has has three reporting segments: Commodity trading, Cryptocurrency mining and Others. Key revenue is generated from Commodity trading.